Dianthus Unveils DNTH312 Dual-Target Autoimmune Therapy
NEW YORK and WALTHAM, Mass., August 4, 2026 Dianthus Therapeutics, Inc. announced the launch of DNTH312, an internally developed...
Nurix Therapeutics
Advertisement
Nurix and Sanofi Advance Oral STAT6 Degrader into Phase 1 Clinical Development
BRISBANE, Calif., August 4, 2026 Nurix Therapeutics, Inc. announced it has earned a $10 million development milestone payment after...
Sanofi’s MenQuadfi Receives EU Approval for Infants From Six Weeks of Age
PARIS, Aug. 4, 2026 Sanofi announced that the European Commission (EC) has approved an expanded indication for MenQuadfi® (Meningococcal...
Nurix Therapeutics Enrolls First Patient in Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg
BRISBANE, Calif., Aug. 4, 2026 Nurix Therapeutics, Inc. announced the enrollment of the first patient in the registrational Phase...
Nurix and Roche Complete Strategic Oncology Collaboration
Brisbane, California, USA | July 21, 2026 Nurix Therapeutics announced the official closing of its previously announced global collaboration...
Advertisements
Roche Partners with Nurix to Advance BTK Degrader Bexobrutideg Across Cancer, Immunology and Neurology
BASEL, Switzerland, June 8, 2026 Roche announced a global licensing and collaboration agreement with Nurix Therapeutics to co-develop and...
Nurix Shows Promising CSU Data for Bexobrutideg
BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...
Nurix Therapeutics Showcases Bexobrutideg Data at EHA
BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...
Bexobrutideg Shows Strong Phase 1 Results in WM Trial
BRISBANE, Calif., December 8, 2025 — Nurix Therapeutics has announced compelling new Phase 1 clinical data for its investigational...
Advertisement
